Erste Asset Management GmbH Invests $4.48 Million in BeiGene, Ltd. (NASDAQ:BGNE)

Erste Asset Management GmbH acquired a new position in BeiGene, Ltd. (NASDAQ:BGNE - Free Report) during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund acquired 20,500 shares of the company's stock, valued at approximately $4,478,000.

A number of other large investors have also added to or reduced their stakes in the company. Blue Trust Inc. boosted its holdings in shares of BeiGene by 156.3% in the 3rd quarter. Blue Trust Inc. now owns 123 shares of the company's stock worth $28,000 after purchasing an additional 75 shares during the period. Allspring Global Investments Holdings LLC purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $36,000. SG Americas Securities LLC purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $105,000. PFG Investments LLC purchased a new position in shares of BeiGene in the 3rd quarter worth approximately $210,000. Finally, Truist Financial Corp boosted its holdings in shares of BeiGene by 10.1% in the 2nd quarter. Truist Financial Corp now owns 1,521 shares of the company's stock worth $217,000 after purchasing an additional 140 shares during the period. Institutional investors own 48.55% of the company's stock.

Insider Buying and Selling at BeiGene

In other news, CEO John Oyler sold 6,175 shares of the company's stock in a transaction dated Tuesday, October 8th. The stock was sold at an average price of $232.22, for a total value of $1,433,958.50. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, insider Xiaodong Wang sold 40,468 shares of the company's stock in a transaction dated Tuesday, November 26th. The stock was sold at an average price of $190.10, for a total value of $7,692,966.80. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 57,845 shares of company stock worth $11,514,300. 7.43% of the stock is currently owned by insiders.

BeiGene Stock Up 0.1 %

NASDAQ:BGNE traded up $0.26 during mid-day trading on Tuesday, hitting $206.01. 395,221 shares of the company's stock traded hands, compared to its average volume of 370,824. The company has a fifty day moving average of $212.45 and a 200 day moving average of $185.24. BeiGene, Ltd. has a twelve month low of $126.97 and a twelve month high of $248.16. The company has a market capitalization of $20.07 billion, a P/E ratio of -25.00 and a beta of 0.57. The company has a debt-to-equity ratio of 0.05, a quick ratio of 1.72 and a current ratio of 1.93.

BeiGene (NASDAQ:BGNE - Get Free Report) last announced its earnings results on Tuesday, November 12th. The company reported ($1.15) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.11) by ($0.04). BeiGene had a negative net margin of 25.94% and a negative return on equity of 25.12%. The business had revenue of $1 billion for the quarter, compared to analyst estimates of $983.26 million. During the same period in the prior year, the company earned $2.01 earnings per share. The company's quarterly revenue was up 28.2% on a year-over-year basis. On average, analysts forecast that BeiGene, Ltd. will post -5.49 EPS for the current year.

Analysts Set New Price Targets

A number of research firms recently issued reports on BGNE. Citigroup boosted their price objective on BeiGene from $269.00 to $288.00 and gave the company a "buy" rating in a report on Thursday, August 8th. JPMorgan Chase & Co. boosted their price objective on BeiGene from $200.00 to $235.00 and gave the company an "overweight" rating in a report on Tuesday, October 22nd. Morgan Stanley restated an "overweight" rating and set a $300.00 price objective on shares of BeiGene in a report on Tuesday. TD Cowen boosted their price objective on BeiGene from $254.00 to $260.00 and gave the company a "buy" rating in a report on Wednesday, November 13th. Finally, JMP Securities assumed coverage on BeiGene in a research report on Wednesday, September 18th. They set a "market outperform" rating and a $288.00 target price for the company. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company's stock. According to MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $253.69.

BeiGene Company Profile

BeiGene, Ltd., through its subsidiaries, engages in the development and commercialization of oncology medicines worldwide. Its products include BRUKINSA to treat various blood cancers; TEVIMBRA to treat various solid tumor and blood cancers; PARTRUVIX for the treatment of various solid tumor malignancies; XGEVA to treat bone metastases from solid tumors and multiple myeloma, as well as giant cell tumor of bone; BLINCYTO to treat acute lymphoblastic leukemia; KYPROLIS to treat R/R multiple myeloma; REVLIMID to treat multiple myeloma; VIDAZA to treat myelodysplastic syndromes, chronic myelomonocyte leukemia, and acute myeloid leukemia; SYLVANT to treat idiopathic multicentric castleman disease; QARZIBA to treat neuroblastoma; POBEVCY to treat metastatic colorectal cancer, liver cancer, and non-small cell lung cancer (NSCLC); BAITUOWEI, to treat breast and prostate cancers; TAFINLAR and MEKINIST to treat NSCLC and melanoma; VOTRIENT for advance renal cell carcinoma; AFINITOR for advance renal cell carcinoma, NET, SEGA, & breast cancers; and ZYKADIA to treat ALK + NSCLC.